Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 8/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 4/20 | 0.38 |
| ▸ | PDE2A | O00408 | 2/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | FPR3 | P25089 | 1/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34469713 | 1.00 | AAK1 (0.45) | AAK1USP30NPC1RECQLRAB9A | |
| SCHEMBL28889626 | 0.80 | DPP8 (0.41) | BACE1PDE2ADPP8DPP9HDAC3 | |
| SCHEMBL17645962 | 0.79 | HDAC3 (0.40) | NPC1RAB9ASMN1; SMN2PDE2AHDAC3 | |
| SCHEMBL2588632 | 0.78 | NPC1 (0.47) | NPC1RECQLRAB9ASMN1; SMN2PDE2A | |
| SCHEMBL17645835 | 0.78 | BACE1 (0.46) | AAK1USP30BACE1PDE2ADPP8 | |
| SCHEMBL5525667 | 0.78 | AAK1 (0.39) | AAK1USP30PDE2AHDAC3HDAC1 | |
| SCHEMBL30722172 | 0.77 | AAK1 (0.38) | AAK1NPC1RAB9APDE2AHDAC3 | |
| SCHEMBL17644060 | 0.77 | DRD2 (0.39) | NPC1RAB9AHDAC3HDAC1HDAC2 | |
| SCHEMBL30510051 | 0.77 | DRD2 (0.39) | NPC1RAB9AHDAC3HDAC1HDAC2 | |
| SCHEMBL1783824 | 0.77 | AAK1 (0.38) | AAK1NPC1RAB9APDE2AHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220281838-A1 | N-METHYL, N-(6-(METHOXY)PYRIDAZIN-3-YL) AMINE DERIVATIVES AS AUTOTAXIN (ATX) MODULATORS FOR THETREATMENT OF INFLAMMATORY AIRWAY OR FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-09-08 | — | — | US | disclosed |
| EP-3204382-B1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-12-01 | — | — | EP | disclosed |
| US-20190233417-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
| US-10253023-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-04-09 | — | — | US | disclosed |
| EP-3204382-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016057500-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016057500-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-14 | — | — | WO | disclosed |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | US | disclosed |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | US | disclosed |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | US | disclosed |
| US-20070185132-A1 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereo | MERCK & CO., INC. | 2007-08-09 | — | — | US | disclosed |
| CN-1816545-A | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | MERCK & CO INC (US) | 2006-08-09 | — | — | CN | disclosed |
| EP-1654259-A1 | CYCLOPROPYL GROUP SUBSTITUTED OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | Merck & Co., Inc. (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005005420-A1 | CYCLOPROPYL GROUP SUBSTITUTED OYAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | MERCK & CO., INC. (US) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253023-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | BTK, SYK, LYN | AAK1 943/4885USP30 2476/4885NPC1 3990/4885 |
| US-20070185132-A1 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereo | IL17A, COASY, OXA1L | AAK1 1392/4885USP30 3983/4885NPC1 1550/4885 |
| US-20220281838-A1 | N-METHYL, N-(6-(METHOXY)PYRIDAZIN-3-YL) AMINE DERIVATIVES AS AUTOTAXIN (ATX) MODULATORS FOR THETREATMENT OF INFLAMMATORY AIRWAY OR FIBROTIC DISEASES | ENPP2, MYT1, INMT | AAK1 1603/4885USP30 2107/4885NPC1 4127/4885 |
| US-20190233417-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | AAK1 856/4885USP30 2804/4885NPC1 4113/4885 |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | AAK1 943/4885USP30 2476/4885NPC1 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.